IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain
India Globalization Capital (NYSE American: IGC) announced receiving patent #10,933,082 from the USPTO on March 2, 2021. This patent covers a cannabinoid composition and method for treating pain associated with Psoriatic Arthritis, Fibromyalgia, Scleroderma, and other conditions. The application was submitted on October 1, 2018. This approval enhances IGC's existing patent portfolio, which already includes patents for seizure and eating disorders.
- Received new patent #10,933,082, enhancing intellectual property.
- Broadens treatment options for pain management in various conditions.
- None.
India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that on March 2, 2021, the Company received one more patent (patent#10,933,082) from the United States Patent and Trademark Office (“USPTO”) for the Company’s cannabinoid composition and method for treating pain in patients with Psoriatic Arthritis, Fibromyalgia, Scleroderma and other conditions. The patent application was filed on October 1, 2018. The latest patent approval adds to the Company’s existing patent portfolio, which includes patent issuances by the USPTO for seizure disorders and eating disorders.
About IGC:
IGC operates two lines of business: (i) infrastructure and (ii) life sciences. The Company is based in Potomac, Maryland, U.S.A. social media: www.igcinc.us, www.igcpharma.com, Twitter @IGCIR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005927/en/
FAQ
What is the recent patent IGC received?
When was the patent application for IGC filed?
How does the recent patent impact IGC's business?
What types of conditions are covered by IGC's new patent?
